hVIVO plc
OPORF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$75.45M
Close$
$0.06
42.2% downside
Current Fair Value
42.2% downsideOvervalued by 42.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $75.45 Million |
|---|---|
| Enterprise Value | $45.02 Million |
| Earnings per Share | $-0.01 |
| Beta | 1.71 |
| Outstanding Shares | 687,966,692 |
Return
| Return on Equity | 59.91% |
|---|---|
| Return on Assets | 30.11% |
| Return on Invested Capital | 39.72% |
Valuation & Multiples
| P/E Ratio | -3.08 |
|---|---|
| PEG | 5.53 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.38 |
| Enterprise Value to EBIT | 1.99 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | 0.31 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 15, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$21.61 M
Consensus analyst estimateNext Earnings Call
Expected Date
April 14, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About hVIVO plc
376 employees
CEO: Yamin Mohammed Khan
hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of...